Search Results for “diagnostic” – Page 53 – media

MEDICA & COMPAMED Düsseldorf 2021

The MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals. The fair takes place once a year in Dusseldorf and is open to trade visitors only. Rising life expectancy, medical progress and the growing awareness of the people for their health are helping to increase the demand for modern treatment methods. This is where the Medica grabs and provides the medical device industry a central market for innovative products and systems that result in an important contribution to the efficiency and quality of patient care. The exhibition is divided into the areas of electromedicine and medical technology, information and communication technology, physiotherapy and orthopedic technology, disposables, commodities and consumer goods, laboratory equipment and diagnostic products. In addition to the trade fair the Medica conferences and forums belong to the firm offer of this fair, which are complemented by numerous activities and interesting special shows. The Medica is held in conjunction with the world's largest supplier fair for medicine, Compamed. Thus, the entire process chain of medical products and technologies are presented to the visitors and necessitates a visit to the two exhibitions for each industry expert.
- Source: drugdu
- 1,207
- August 26, 2021
The New CRISPR-Based Covid-19 Test Could Be a Game-Changer

A new test based on gene targeting technology CRISPR could diagnose Covid-19 infections in 45 minutes. It was recently outlined in a paper in the journal Nature Biotechnology.
- Source: drugdu
- 1,545
- August 26, 2021
Covid-19 Covid-19 Test gene targeting technology
Alchemab to collaborate with AstraZeneca on prostate cancer research

Cambridge-based biotech company Alchemab has announced a new collaboration with British pharma AstraZeneca (AZ), aiming to accelerate research for prostate cancer. As part of the collaboration, Alchemab and AZ will collaborate on a proof-of-concept study to improve understanding of the ‘fundamental biology’ of prostate cancer. Alchemab will utilise its novel drug discovery platform as a diagnostic tool through the identification of disease biomarkers, with the potential to inform the development of new antibody-based medications. Under the agreement, Alchemab will sequence and explore antibody repertoires in patient samples gathered from a clinical trial of an undisclosed immuno-oncology agent within AZ’s pipeline. Alchemab may also be able to identify antibody sequence patterns that could be used as biomarkers for early detection and patient stratification by classifying patients into two groups – responders and non-responders. The overall purpose of the collaboration is to identify novel and disease-relevant antibodies which may generate therapeutic insights into ...
- Source: drugdu
- 373
- May 7, 2021
AstraZeneca
New NHS Medtech Funding Mandate welcomed by BIVDA

The UK trade association for in vitro diagnostics (IVD) companies BIVDA has welcomed the NHS Medtech Funding Mandate, a new policy aimed at accelerating the uptake of medical devices, diagnostics and digital products in the NHS. The new Mandate, which will come into effect from 1 April 2020, will aim to enable patients to access ‘pioneering’ IVD devices faster and with greater ease. For products to qualify under the Mandate, they must demonstrate that they are effective, deliver material savings to the NHS, are cost-saving in-year and are affordable to the NHS. The Mandate policy is set to be published annually in December, following a review and feedback improvement cycle. A list of technologies that meet the MedTech Funding Mandate criteria is expected to be published before the end of July. “The publication of the Mandate is an opportunity to celebrate the UK as a leader in technologies for health ...
- Source: drugdu
- 250
- January 30, 2021
IVD
ATCC introduces new product segment with launch of SARS-CoV-2 external control kit

ATCC, the world’s premier biological materials management, and standards organization, today announced the introduction of its new SARS-CoV-2 External Control Kit for clinical laboratories and test manufacturers. Image Credit: ATCC The ready-to-run kit provides controls in the rapidly changing COVID-19 testing landscape as a workflow-optimized kit with complete genome coverage that’s widely compatible with most commercial and laboratory-developed tests. Federal regulation requires that clinical laboratories assess the performance of their testing applications. This new ATCC kit is a practical, kitted solution clinical laboratories can use to meet this requirement. Validated, convenient, and ready-to-use, it offers a universal, full-process positive control (a heat-inactivated virus) and negative control (human cell line) that allow clinical laboratories to easily and accurately verify and assess the quality of their molecular diagnostic assays. The SARS-CoV-2 External Control Kit is compatible with most molecular diagnostic tests being used today. This broad compatibility is critical as surveys from the ...
- Source: drugdu
- 265
- December 4, 2020
SARS-CoV-2 external control kit
Closing In On The Cause Of Alzheimer’s Disease

The unpredictability of Alzheimer’s disease may be partly caused by changes in star-shaped cells in the brain called astrocytes, find scientists from South Korea. AsianScientist (Dec. 1, 2020) – Despite decades of scientific research, Alzheimer’s disease and its causes still largely remain a mystery. Now, scientists from South Korea have identified a key indicator associated with neurodegeneration in Alzheimer’s. Their findings was published in Nature Neuroscience. Poignantly depicted in Hollywood films like The Notebook and Still Alice, Alzheimer’s disease is a brain disorder that accounts for a majority of cases of dementia, the progressive loss of memory and other cognitive abilities. Over the years, numerous hypotheses regarding the cause of Alzheimer’s have been presented. Perhaps the most prominent is the amyloid hypothesis, which pins the progression of Alzheimer’s on the build-up of beta-amyloid (Aβ) plaques in the brain. These plaques block cell signalling—potentially triggering inflammation and leading to brain cell ...
- Source: drugdu
- 404
- December 2, 2020
Alzheimer's disease
FDA authorises first home self-testing kit for COVID-19

RELATED TAGS: Lucira Health, Us, emergency use authorization, COVID-19 The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the Lucira COVID-19 All-In-One Test Kit: the first COVID-19 diagnostic test for self-testing at home. Lucira says the kit takes around two minutes to use; and gives rapid results within 30 minutes. The $50 kit – which fits in the palm of the hand – provides a simple ‘positive’ or ‘negative’ reading. The kit is a molecular (real-time loop mediated amplification reaction) single use test that is intended to detect the novel coronavirus SARS-CoV-2 that causes COVID-19. It is authorized for prescription home use with self-collected nasal swab samples in people aged 14+ who are suspected of having COVID-19 by a healthcare provider. “While COVID-19 diagnostic tests have been authorized for at-home collection, this is the first that can be fully self-administered and provide results at ...
- Source: drugdu
- 347
- November 21, 2020
Covid-19
FDA warns of COVID-19 antigen test false positives as report flags Quidel on accuracy

FDA has issued an alert to clinical labs and healthcare providers about the potential for COVID-19 antigen tests to deliver false positives after receiving reports from nursing homes and other settings. The agency’s Tuesday notice reminds users to follow the instructions, noting that improper storage and reading the results at the wrong time can lead to false results. At the same time, the agency said false positives could be an inevitable consequence of using tests with specificities below 100%. If a test with 98% specificity is used to screen a population in which 10% of people are infected, two out of every 10 positive results will be false. The FDA’s warning comes a day after The New York Times reported on a University of Arizona study raising concerns about the ability of a Quidel rapid antigen test to detect asymptomatic cases. The study found Quidel’s test produced more false positives than positives confirmed by the gold standard PCR tests. The potential for antigen tests ...
- Source: drugdu
- 392
- November 9, 2020
Covid-19
Natural COVID-19 Infection Produces Robust T Cell Response and Memory to Fight Future Infections, Finds Study

By HospiMedica International staff writers Posted on 08 Sep 2020 Researchers from the University of Oxford (Oxford, UK) have found that natural infection with COVID-19 produces a robust T cell response, including inducing T cell ‘memory’ to potentially fight future infections. While research has shown that COVID-19 induces a B cell antibody response, it has been less clear whether COVID-19 causes the immune system to make virus-specific T cells too, and whether they are important for recovery from the initial infection, and protection against new infections. While antibodies latch onto and destroy disease-causing agents like viruses and bacteria, T cells latch on to diseased cells within the body, such as tumor cells or virus-infected cells. T-cells also help attract other immune cells to the area. T cells are attracted to tumor or viral protein fragments (called epitopes) displayed on the surface of diseased cells, which act like waving a flag ...
- Source: https://www.hospimedica.com/covid-19/articles/294784403/natural-covid-19-infection-produces-robust-t-cell-response-and-memory-to-fight-future-infections-finds-study.html
- 242
- September 9, 2020
Oversensitive COVID-19 Tests Detecting Dead Coronavirus Cells, Driving False Positives and Reinfections

A study by the Oxford University’s Centre for Evidence-Based Medicine (Oxford, England) suggests that the current COVID-19 diagnostic tests could be too sensitive and may be detecting dead coronavirus cells, leading to overestimated infections. According to the researchers, the tests used to diagnose COVID-19 are so sensitive that they may be indicating people are infected with SARS-CoV-2 even when they had the virus 70 days ago. Prof Carl Heneghan, director of the Centre for Evidence-Based Medicine, believes that eight days after contracting COVID-19, the chances of an infected person passing on the virus to others become zero if there are no symptoms. However, fragments of the coronavirus can still remain in the body for several weeks afterwards. Polymerase chain reaction (PCR) tests currently used to detect SARS-CoV-2 have technical limitations as they cannot distinguish whether the virus in the patient is alive or dead. The researchers analyzed 25 studies on ...
- Source: https://www.hospimedica.com/covid-19/articles/294784371/oversensitive-covid-19-tests-detecting-dead-coronavirus-cells-driving-false-positives-and-reinfections.html
- 192
- September 9, 2020

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.